IL-33 Biotinylated Protein: Functional Analysis and Research Tools of a Type 2 Immunity Alarmin

Author: Senior Product Manager of UA Views：16

This article focuses on the molecular characteristics and biological functions of interleukin-33 (IL-33), systematically elaborating its expression regulation and activity modulation mechanisms as an IL-1 family alarmin in barrier tissues, analyzing the functional network by which IL-33 activates type 2 immune cells such as ILC2s, mast cells, eosinophils, and Th2 cells through the ST2 receptor, and exploring the pathological driving role of IL-33 in type 2 inflammatory diseases such as allergic asthma as well as its targeted therapeutic potential.

Recent Advances
Product Information

Recent Advances

Biotinylated IL-33 Protein: Functional Analysis of a Type 2 Immune Alarmin and Research Tool

Brief Introduction: This article focuses on the molecular characteristics and biological functions of interleukin-33 (IL-33), systematically elaborating its expression regulation and activity modulation mechanisms as an IL-1 family alarmin in barrier tissues, analyzing the functional network through which IL-33 activates type 2 immune cells such as ILC2s, mast cells, eosinophils, and Th2 cells via the ST2 receptor, and discussing the pathological driving role and targeted therapeutic potential of IL-33 in type 2 inflammatory diseases such as allergic asthma.

I. Molecular Characteristics and Expression Distribution of IL-33.

Interleukin-33 is a member of the IL-1 family and an important cytokine of the immune system, participating in various allergic diseases and other inflammatory responses. As an alarmin, IL-33 is primarily expressed when endothelial cells and epithelial cells of the intestine, skin, and lungs undergo necrosis or lysis. Due to its special expression location, IL-33 generally resides at barrier sites to "survey" viral and parasitic infections as well as the invasion of harmful substances or allergens. This specific expression pattern in barrier tissues makes IL-33 the body's first molecular line of defense for sensing external stimuli and initiating immune responses.

II. Molecular Structure and Activity Regulation Mechanisms of IL-33.

The full-length IL-33 molecule consists of three parts: a chromatin-binding domain, a protease-sensitive domain, and a receptor-binding domain. Because the chromatin-binding domain has a strong binding capacity to nuclear chromatin, IL-33 is not easily released from apoptotic cells, thereby extending its half-life. Compared to a single IL-33 molecule, the complex of IL-33 and histones is more readily released from cells and exhibits stronger activity. In addition, certain proteases from mast cells, neutrophils, or allergens can cleave IL-33, and the cleaved IL-33 exhibits enhanced activity. This protease-mediated activation mechanism allows IL-33 to rapidly amplify its biological effects in the inflammatory microenvironment.

The activity of IL-33 is controlled by numerous factors. When not released, IL-33 may be cleaved by intracellular caspases, thereby losing its ability to activate proteins and preventing immune responses from occurring. The receptor-binding domain of IL-33 contains 4 cysteine residues. Once released from apoptotic cells, due to the different extracellular environment, these 4 cysteines rapidly oxidize or form disulfide bonds with each other, causing IL-33 to lose its ability to bind to the receptor and thus lose its activity. This oxidation process is very rapid, completing within 1 hour of release from the cell. Furthermore, IL-33 activity is also influenced by the signaling level of its receptor. IL-33 binds with high affinity to its receptor ST2 and then recruits IL-1RAcP, subsequently exerting its effects through a series of signaling proteins. This multi-layered regulatory mechanism ensures that IL-33 exerts its immune functions under appropriate spatiotemporal conditions.

III. Receptor Expression of IL-33 and Type 2 Immune Cell Activation.

Numerous innate and adaptive immune cells express ST2, including mast cells, eosinophils, basophils, macrophages, type 2 innate lymphoid cells, Th2 cells, and regulatory T cells. IL-33 can activate these cells, inducing type 2 immune responses. IL-33 induces basophils and mast cells to secrete IL-4 and IL-13, which in turn cause B cells to produce IgE. IL-33 can promote mast cell degranulation and cytokine release without requiring the IgE-FcεRI signaling pathway, and can directly stimulate eosinophil degranulation, prolonging eosinophil survival. IL-33 promotes antigen-specific Th2 cells to secrete IL-13, and IL-5-producing Th2 cells are important targets of IL-33, causing airway inflammation. IL-33 can cause Tregs to lose their suppressive capacity, instead promoting Tregs to increase ST2 and other type 2 cytokine expression. This broad activation capacity across multiple immune cell subsets makes IL-33 a core initiating factor of type 2 immune responses.

IV. The Core Role of IL-33 in Epithelial Barriers and Pulmonary Immunity.

At epithelial barrier sites, allergen exposure promotes epithelial cell proliferation and expression of large amounts of IL-33; the accumulation of IL-33 stimulates ILC2s to rapidly produce type 2 cytokines such as IL-5 and IL-13. ILC2s may be the most important cells in IL-33 signaling. A study compared the ability of ILC2s and Th2 cells to produce type 2 cytokines and found that even though Th2 cells are numerically dominant, ILC2s produce more type 2 cytokines, particularly IL-5 and IL-13. Mouse models show that under allergen exposure, IL-33 can cause ILC2s to migrate from the bone marrow to the lungs, recruiting ILC2s to accumulate in the lungs. IL-33 plays an important role in pulmonary immune responses. These findings establish the core position of the IL-33-ILC2 axis in pulmonary type 2 immunity.

V. Pathological Driving Role and Therapeutic Potential of IL-33 in Allergic Asthma.

Most childhood asthma and 50% of adult asthma belong to the type 2 inflammatory type, characterized by increased eosinophils in the airways and blood, excessive mucus production, and elevated IgE levels. Whether in children or adults with asthma, if IL-33 concentrations increase, symptoms become more severe. Bronchial epithelial cells and airway smooth muscle cells express IL-33, which is associated with airway hyperresponsiveness in asthma patients. Allergen exposure or viral infection can stimulate IL-33 secretion and lead to the development of asthma, which explains why severe respiratory viral infections and allergen exposure in early life are risk factors for asthma onset.

Inhibiting the IL-33 signaling pathway may be a novel target for treating allergic diseases, particularly in early life, where inhibiting IL-33 may potentially prevent the development of allergic diseases. In IL-33-related basic research and drug development, high-quality recombinant IL-33 protein is a core tool for dissecting its signal transduction mechanisms and evaluating its biological functions. Biotinylated IL-33 protein can be used for high-sensitivity detection and binding analysis based on the streptavidin-biotin system.

VI. Conclusion.

In response to the needs of IL-33 function research and detection method development, Univ provides IL-33 Protein, Mouse. This product is suitable for applications including mouse IL-33/ST2 signaling pathway mechanism research, ILC2 and Th2 cell function regulation research, IL-33 function research in allergic asthma models, and the establishment and validation of IL-33 immunoassays. Biotinylated IL-33 protein can be combined with streptavidin-conjugated detection systems for receptor binding activity analysis and flow cytometric detection of cell surface ST2 expression.

As an important alarmin in the IL-1 family, IL-33, by virtue of its specific expression pattern in barrier tissues, multi-layered activity regulation mechanisms, and its broad activation capacity through the ST2 receptor for ILC2s, mast cells, eosinophils, and Th2 cells, plays an irreplaceable core role in type 2 immune responses and the pathological processes of allergic asthma. Its key position in early-life allergen exposure and respiratory viral infection-induced asthma development makes IL-33 an important target for the prevention and treatment of allergic diseases. IL-33 Protein, Mouse provides reliable tool support for the in-depth analysis of the IL-33 signaling network and the development of related disease treatment strategies, and will continue to drive innovative exploration in the field of type 2 inflammation research.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Next